senti-202
senti-202: developed by 1 company · 1 clinical trial tracked.
senti-202 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect senti-202 to SNTI; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could senti-202 → SNTI affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
AML/MDS
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Senti Biosciences, Inc. (SNTI) AML/MDS | Phase 1 |
Clinical Trials (1)
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies
Primary endpoint: Safety and tolerability for dose determination of SENTI-202
Interventionalopen21 targetStarted 2024-04Completion 2040-088 sites · Australia, United StatesSenti Biosciences
Frequently asked questions
Who is developing senti-202?
senti-202 is being developed by Senti Biosciences, Inc..
How many clinical trials involve senti-202?
BioSniper tracks 1 clinical trial involving senti-202.